Adelle

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adelle

Quick Facts

Property Description
Active ingredient Drospirenone and Ethinyl Estradiol
Form Oral Tablets
Pharmacological class Combined Hormonal Contraceptive (CHC)
General purpose Prevention of Pregnancy (Contraception)
Origin Synthetic Hormonal Preparation

Adelle: Definition and Pharmacological Classification

Adelle is a prescription-only medication officially classified as a Combined Hormonal Contraceptive (CHC) within the broader pharmacological class of Estrogens and Progestins. This designation confirms it is a dual-component treatment utilizing two different types of synthetic hormonal preparation. This drug is a fixed-dose combination product, where the active components are present in the same concentrations across all active oral tablets intended for systemic administration. The use of such combination oral contraceptives is widely clinically recognized for effective fertility management in women of reproductive age.

Composition and Pharmaceutical Form: Drospirenone and Ethinyl Estradiol

The primary active ingredients in Adelle are Drospirenone (a synthetic progestin) and Ethinyl Estradiol (a synthetic estrogen), which are combined in a single oral tablet. Drospirenone is chemically distinct, possessing both antimineralocorticoid and antiandrogenic activity, properties that set it apart from many older progestins used in comparable preparations. This feature is a key differentiating factor of the formulation. The physical form is an oral tablet, which includes tablet excipients that ensure accurate formulation and stable systemic delivery of the active compounds.

General Therapeutic Purpose of Adelle

The essential therapeutic purpose of Adelle is the highly reliable prevention of pregnancy, achieved through its function as a contraceptive. The coordinated presence of synthetic estrogen and synthetic progestin ensures that the drug performs its primary role by simultaneously suppressing the release of an egg and inhibiting conditions favorable for conception. The overall goal of this hormonal combination is to provide effective, regular contraception when used as directed by women of reproductive age.

Regulatory References

  1. Label: DROSPIRENONE AND ETHINYL ESTRADIOL kit - DailyMed - NIH

What side effects are possible with Adelle?

The official safety documentation for Adelle (Drospirenone/Ethinyl Estradiol) classifies adverse reactions based on frequency and body system, strictly according to government regulatory standards. The primary safety concern documented is the rare but serious risk of thromboembolic events, including Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE) (e.g., stroke and myocardial infarction).

Adverse Reaction Scope

Classification Examples of Documented Effects (by System-Organ Class)
Common Nervous System: Headache, migraine. Psychiatric: Mood changes, depression. Reproductive: Breast pain, spotting/irregular bleeding. Gastrointestinal: Nausea.
Rare VTE, ATE, Benign/Malignant Liver Tumors.

Safety Constraints and Special Populations

Official labeling defines specific safety limitations. The risk of VTE is documented as being highest during the first year of use. The medication is generally contraindicated in individuals with a history of thromboembolic disorders, severe hepatic disease, or known adrenal insufficiency. Additionally, the risk of serious cardiovascular events is elevated in smokers over age 35, and caution is advised for patients with renal insufficiency due to the drospirenone component’s documented potential for hyperkalemia.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Adelle (Drospirenone and Ethinyl Estradiol) indicates that acute overdose is generally not likely to be life-threatening.

Documented Overdose Presentations

Symptoms reported in regulatory documents following overexposure are typically limited to non-severe manifestations:

  • Gastrointestinal: Nausea and vomiting.
  • Reproductive: Vaginal bleeding, often occurring as withdrawal bleeding.

No specific severe outcomes (e.g., blood clots) are formally documented as a direct result of acute overexposure in the official overdose sections.

Immediate Actions and Management

Action Required Management Focus
Seek immediate medical attention for suspected overexposure. No specific antidote is known; treatment is symptomatic and supportive.
Contact the Poison Help line for urgent guidance (e.g., 1-800-222-1222 in the US). Monitoring of serum potassium and sodium is recommended due to the anti-mineralocorticoid activity of the drospirenone component.

When to Seek Urgent Help (Label-Derived Phrasing):

Immediate medical assistance is required for suspected overexposure. Medical professionals may also advise seeking urgent help if symptoms typical of more serious side effects (e.g., concerning pain, vision changes) are observed, even though these are not typical acute overdose signs.

Connection to the Overdose Profile:

The official profile defines Adelle overdose as low-risk for acute severity, presenting primarily with nausea and vaginal bleeding. Nevertheless, regulatory guidance mandates seeking immediate medical attention for any overexposure. Management is strictly defined as supportive care, with the unique requirement to monitor for potential potassium and sodium imbalances due to the drospirenone component's specific activity.

Therapeutic Uses of Adelle

What Adelle Treats: Main Uses and Benefits

This medication is commonly used in situations involving the management of reproductive health and the prevention of pregnancy. It is applied across domains where hormonal regulation is needed to address specific physiological needs related to the menstrual cycle and fertility management.

The primary therapeutic areas involve prevention of conception, regulation of the menstrual cycle, management of moderate acne, and support for symptoms associated with premenstrual dysphoric disorder. It is commonly used when reliable, daily hormonal support is needed to address manifestations that interfere with routine reproductive health.

“This supportive management is applied when appropriate for easing challenging manifestations, which may assist with maintaining functional stability and hormonal balance when symptoms are more noticeable.”

Enhancing Cycle Regularity and Symptom Management

This domain is relevant for managing symptoms that interfere with daily comfort, such as irregular cycles, heavy bleeding, or physical discomfort linked to hormonal fluctuations. The medication is used in situations involving certain distressing symptoms and contributes to improved day-to-day comfort by supporting hormonal consistency, and may assist with maintaining physiological stability.

Quick Fact: Relief for Hormonal Fluctuations This medication is considered relevant for easing symptom clusters that may become intense or disruptive during the cycle, and may assist with maintaining functional stability during hormonal fluctuations.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Population Eligibility for Adelle

The eligibility profile for Adelle (Drospirenone and Ethinyl Estradiol) is strictly defined by regulatory documents, classifying populations into allowed, restricted, and contraindicated groups. The medicine is indicated for use by females of reproductive potential for contraception.

Populations Who Must Not Use Adelle (Contraindications)

According to official labeling, Adelle is contraindicated in several specific populations due to heightened risk:

  • Females over 35 years old who smoke.
  • Individuals with a history of arterial or venous thrombotic diseases, including deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction.
  • Patients with known or suspected breast cancer or other hormone-sensitive cancers.
  • Those with severe hepatic impairment, liver tumors, severe renal impairment, or adrenal insufficiency.
  • Women with uncontrolled hypertension or diabetes mellitus with vascular involvement.
  • Women with migraine with focal neurological symptoms (aura).

Age and Reproductive Status Limitations

Adelle is not indicated for use before menarche (the first menstrual period) or for postmenopausal women. Use is contraindicated during a known pregnancy and not recommended for women who are actively breastfeeding.

What should I know about interactions with other medicines?

Adelle is subject to several officially documented interaction patterns primarily involving hepatic metabolism and pharmacodynamic effects. Co-administration is contraindicated with specific Hepatitis C Virus (HCV) drug regimens containing Ombitasvir, Paritaprevir/Ritonavir, with or without Dasabuvir, due to the potential for significant liver enzyme elevation.

Strong CYP3A4 inducers, such as Phenytoin or Rifampin, cause a pharmacokinetic interaction leading to reduced plasma exposure of the contraceptive components, which may reduce effectiveness. Conversely, strong CYP3A4 inhibitors like Ketoconazole may increase the exposure of both active ingredients. The herbal product St. John's Wort is also documented as an enzyme inducer and is restricted for co-use.

A key pharmacodynamic interaction exists with Potassium-Elevating Medications, including Potassium-Sparing Diuretics (e.g., Spironolactone). Due to Drospirenone's anti-mineralocorticoid activity, this combination increases the risk of hyperkalemia in susceptible patients, necessitating mandatory monitoring during the initial treatment cycle. Population-specific cautions note this risk is heightened in patients with renal impairment, hepatic impairment, or adrenal insufficiency.

Timing-based constraints require that Bile Acid Sequestrants be administered at least 4 hours apart from Adelle to prevent reduced absorption.

Mechanism of Action

Targeting Central alpha2-Adrenergic Receptors

This drug primarily acts as an agonist (activator) at alpha-2 adrenergic receptors (alpha2-ARs) located mainly in the central nervous system. This molecular interaction initiates the drug's effect by engaging the presynaptic alpha2-AR-mediated autoregulatory mechanism for norepinephrine.


⬇️ Modulating Central Sympathetic Outflow

Activation of these central alpha2-ARs triggers a negative feedback loop that reduces the release of the neurotransmitter norepinephrine. This action reduces the intensity of signals transmitted from the central nervous system to the periphery, which modulate physiological processes, including heart rate and vascular tone.


️ Leading to Reduced Heart Rate and Vascular Tone

By diminishing the overall central sympathetic drive, this mechanism produces the resulting physiological effects of a decreased heart rate and peripheral vasodilation (widening of blood vessels). These changes result in a decrease in systemic arterial pressure and affect central nervous system activity, which includes the observation of sedation.

Dosage and Administration Information

How Adelle is Used: Official Administration Guidelines

Adelle (Drospirenone and Ethinyl Estradiol) is administered exclusively through the oral route as a fixed-dose combination oral tablet. Usage guidelines focus on a precise daily, sequential administration to ensure proper use.


Standard Dosing Regimen

Adelle is taken according to a continuous, 28-day cyclic schedule. The most common administration schedule involves taking one tablet daily for 28 consecutive days:

  • Active Tablets: Typically 24 consecutive days of hormone-containing tablets (3 mg Drospirenone and 0.02 mg Ethinyl Estradiol).
  • Placebo Tablets: Followed by 4 consecutive days of inert (placebo) tablets, as indicated by the blister pack order.
  • Cycle Continuity: Each new 28-day cycle must begin immediately after the last tablet of the previous pack is taken, without a break in daily administration.

Key Administration Requirements

Instruction Requirement Details
Frequency and Timing One tablet must be taken daily at the same time every day to maintain a consistent dosing interval.
Tablet Order Tablets must be taken in the order directed on the blister pack, ensuring the active tablets are taken sequentially before the inert tablets.
Food Intake Administration is flexible; the tablet can be taken with or without food.

Use for Specific Populations

Specific guidelines apply to certain patient groups:

  • Pediatric Use: The medication is indicated only for use in females after menarche (the onset of menstruation).
  • Geriatric Use: Use is not indicated in postmenopausal women, as it is outside the intended patient population.

Starting the First Pack

Standard protocols exist for initiating treatment, such as the Day 1 Start (starting on the first day of menses) or Sunday Start. If the tablet is started later than the first day of the menstrual cycle, a non-hormonal back-up method of contraception should be used for the first 7 consecutive days of active tablet use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adelle


Evidence for Preventing Pregnancy (Contraception)

Research has examined the use of this medication in preventing pregnancy through extensive clinical trials and large, long-term observation. These studies monitored outcomes in women of reproductive age by tracking the frequency of unintended pregnancies, often using the Pearl Index (PI)—a measurement tool that tracks outcomes per 100 woman-years of use. Research also examined patterns of cycle control, including the timing and incidence of bleeding or spotting, which contributes to understanding patient-reported experiences during continuous use.

Findings describe patterns observed in the studies related to the Pearl Index measurements, which are the main focus of these trials. Preventing pregnancy was evaluated in research for this drug class, and the studies monitored these outcomes over intermediate-term follow-up periods, typically 1 to 2 years in controlled settings.


Evidence for Managing Moderate Acne

This part describes the randomized, controlled trial designs that examined the use of this medication for moderate acne, outlining what specific outcomes related to physical discomfort and inflammatory or irritative states were measured in these studies. The research primarily consisted of randomized, controlled trials, including those comparing outcomes to a placebo, which were conducted during periods of increased symptom activity in women with a clinical diagnosis of moderate acne vulgaris who were also seeking contraception.

Outcomes Measured in Acne Trials

Studies focused on outcomes linked to inflammatory or irritative states related to skin appearance. Specific measures included tracking the change in lesion counts (such as inflammatory and non-inflammatory spots) and the use of physician-rated scales, such as the Investigator's Global Assessment (IGA), to describe overall skin changes. These findings contribute to the broader evidence landscape when the medicine was observed in research exploring short-term symptom changes.


Evidence for Managing Symptoms of Premenstrual Dysphoric Disorder (PMDD)

This section outlines the placebo-controlled research that was conducted during periods of increased symptom activity for this specific indication. These trials was studied for women with a confirmed diagnosis of moderate-to-severe PMDD, a condition characterized by fluctuating or episodic manifestations. Research examined patient-reported outcomes describing perceived discomfort across affective (mood and irritability) and physical symptom domains using structured daily diary assessment scales.

Focus on Affective and Somatic Symptoms

Studies explored specific symptom clusters of PMDD by separating and measuring the intensity of affective symptoms and somatic symptoms. This approach was applied in studies examining patient-reported experiences to research how symptoms evolved in the observed populations during the trials. These outcomes were observed in research exploring short-term symptom changes over defined time intervals, typically covering three menstrual cycles.


Long-Term Studies and Extended Follow-up

The main efficacy trials for acne and PMDD often have relatively limited follow-up durations. For the primary use in contraception, large observational settings evaluating daily-life functioning were studied for monitoring patterns over much longer timeframes. Long-term data was observed in large datasets to study outcomes that are not fully characterized in the shorter controlled trials, particularly concerning very rare systemic outcomes.


Study Limitations and Research Gaps

Despite the research that was observed in controlled trials, data for certain groups remain insufficient. For the non-contraceptive uses (PMDD and acne), results apply only to the populations studied—women who also chose an oral contraceptive method. There is limited information for long-term outcomes regarding the sustained duration of effectiveness for PMDD or acne. Furthermore, the extensive datasets necessary to evaluate the patterns related to very rare systemic or vascular events are mainly derived from large observational studies, where comparative evidence is lacking in the highly controlled manner of RCTs. While much was studied for, research exploring specific long-term outcomes is still ongoing, and the certainty remains low in some areas.

Key Studies & References

  1. FDA Approved Patient Labeling Guide for Using Drospirenone and Ethinyl Estradiol Tablets (Product Labeling for Contraception, PMDD, and Acne)
  2. Combined hormonal contraception and the risk of venous thromboembolism: A guideline - American Society for Reproductive Medicine (ASRM)

Frequently Asked Questions (FAQ)

Common questions about Adelle (FAQ)

Q: How long does it typically take to feel the effects of Adelle after taking it?

Official documents state that the body requires at least 7 consecutive days of correct use before the contraceptive effect is established. Regulatory guidance states that a non-hormonal back-up method should be considered for the first week for pregnancy prevention. This allows the body to fully adjust and establish the medication's intended effect.

Q: How long does a single dose of Adelle last?

Official administration instructions specify that one tablet must be taken daily at the same time every day. This dosing regimen is designed to maintain a consistent level of the active hormones in the body over a 24-hour period. Consistent, timely intake is emphasized to help maintain the medication's intended function.

Q: Does Adelle require any routine laboratory tests or monitoring?

Regulatory information indicates that routine monitoring is part of the overall treatment plan. This typically involves regular gynecological check-ups and may also include checking blood pressure and blood sugar. Monitoring for high potassium levels is necessary when co-administered with certain interacting medications.

Q: How does the action of Adelle differ from other medications in the same class?

Official product information highlights that the progestin component, Drospirenone, is chemically unique. This ingredient is noted for having both anti-mineralocorticoid and anti-androgenic activity. These are documented features that differentiate it from some other combined hormonal contraceptives.

Q: Is it common to experience loss of appetite while taking Adelle?

Loss of appetite has been noted in clinical contexts, although nausea is listed as a more common side effect in official safety documents. Loss of appetite is also documented as a potential symptom of liver injury, which is a severe, rare adverse reaction, according to safety documentation.

Q: Can Adelle cause or worsen anxiety or nervousness?

Official safety documentation lists psychiatric side effects, specifically 'mood changes' and 'depression,' among the common adverse reactions. This indicates that the medication can impact mood regulation. These symptoms are part of the established adverse reaction profile.

Q: Is Adelle generally considered appropriate for people with a history of heart issues?

According to the official population eligibility criteria, the medicine is strictly contraindicated for individuals with a history of arterial or venous thrombotic diseases. This also applies to those with uncontrolled hypertension or certain heart rhythm or valve problems. Official documentation outlines these restrictions due to heightened risk.

Q: Are there any long-term studies on the effects of Adelle?

Studies and official information indicate that while controlled trials for non-contraceptive uses are often short-term, large observational settings are used to monitor the long-term patterns for the primary use (contraception). These studies monitor for very rare systemic outcomes over extended time periods.

Q: How does the effectiveness of generic Adelle compare to the brand-name drug?

Regulatory agencies require generic versions of the drug to demonstrate bioequivalence to the original brand-name product to achieve approval. Bioequivalence means the generic is expected to perform the same as the brand-name drug in the body.

Q: What happens in the body if a person stops taking Adelle suddenly?

Official product information indicates that discontinuing the tablets is associated with the return of the body’s natural menstrual cycle and hormone levels. The return of fertility is generally prompt once the medication is stopped. The return of pre-existing symptoms, like acne or heavy periods, may also occur.

Q: What should be done if a dose of Adelle is forgotten?

Regulatory guidance provides specific, detailed instructions for a missed dose based on the number of tablets missed and the timing within the monthly cycle. These instructions should be reviewed carefully to ensure proper use. Generally, if one active tablet is missed, it should be taken as soon as it is remembered.

Q: Can Adelle cause unexplained weight changes?

Official safety documentation lists weight change and weight gain as possible, commonly reported adverse reactions. This information is included in the comprehensive safety profile of the medication.

Q: Is it normal to feel a temporary crash or fatigue as Adelle wears off?

General tiredness or feeling weak is documented in the safety information as a possible adverse reaction. Official sources describe this as part of the overall adverse reaction profile.

Q: Can Adelle affect people with pre-existing mood disorders?

Because the drug is indicated for PMDD (a condition related to mood) and lists mood changes and depression as common side effects, it is understood that the medication can affect mood regulation. This is part of the established adverse reaction profile outlined in official documentation.

Q: Can Adelle cause visual changes or blurred vision?

Visual changes or loss of vision are documented in safety information as potential signs of serious, rare adverse events, such as a blood clot or stroke. These are considered symptoms documented in safety information that indicate a potential serious adverse event.

Q: Does Adelle have any known sexual side effects?

Official safety documentation lists lowered interest in sex (decreased libido) among the possible adverse reactions. This is part of the comprehensive safety profile detailed in official documents.

Q: What are the official regulatory positions on Adelle use during pregnancy or breastfeeding?

According to official regulatory documents, use of this medication is strictly contraindicated during a known pregnancy. Furthermore, its use is generally not recommended for women who are actively breastfeeding.

Q: What are the signs of a serious allergic reaction to Adelle?

Official safety documents describe signs of a serious allergic reaction, which include skin rash, hives, itching, and swelling of the face, lips, tongue, or throat. These symptoms are considered warnings documented in safety information that indicate a potential serious adverse event.

Q: Can Adelle affect kidney or liver function?

Official labeling states the medication is strictly contraindicated in individuals with severe hepatic (liver) or severe renal (kidney) impairment. Rare adverse reactions documented in official sources also include the development of benign or malignant liver tumors.

Q: Why are there different forms or salts of the active ingredient in Adelle?

Official documents state that Adelle is a fixed-dose combination product containing two distinct active ingredients: Drospirenone and Ethinyl Estradiol. These two synthetic hormonal preparations are combined in a single oral tablet to achieve the primary therapeutic purpose of the medication.

How should Adelle be stored and disposed of?

How to Store and Dispose of Adelle

Adelle (Drospirenone and Ethinyl Estradiol) must be stored according to regulatory requirements to maintain its stability.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature (20 C to 25 C); do not freeze.
Protection Keep away from excess heat, moisture, and direct light.
Container Must be kept in the original container and stored tightly closed.

Safety and Disposal

Adelle must be stored out of the sight and reach of children and should not be used past its expiration date.

Regulatory instructions advise that unused or expired tablets should be thrown away and recommend consulting a healthcare professional or utilizing a drug take-back program for proper disposal. The tablets should not be flushed down a toilet or poured into a drain unless specific instruction is provided on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adelle found in:

A-Z Index: